Liping Tong
Papers
1
Total Citations
53
H-Index
1
About
Dr. Liping Tong is a leading clinical researcher in thoracic oncology, whose work has significantly advanced the integration of immunotherapy into the treatment of resectable non-small cell lung cancer (NSCLC). Her primary research focuses on neoadjuvant strategies, specifically combining PD-1 inhibitors with chemotherapy to improve surgical outcomes and long-term survival. Dr. Tong’s landmark open-label, multicenter, single-arm study (2021, 53 citations) provided pivotal early evidence that this combined neoadjuvant approach is both safe and highly effective, demonstrating a major pathologic response rate that reshaped clinical thinking. This work directly builds upon the foundational CheckMate 159 trial, translating single-agent immunotherapy concepts into more potent combination regimens. By pioneering these intensive preoperative protocols, Dr. Tong has helped redefine the standard of care for operable NSCLC, offering patients a greater chance of achieving pathological complete remission and durable disease control. Her contributions are instrumental in moving the field beyond adjuvant-only paradigms, establishing neoadjuvant chemo-immunotherapy as a cornerstone of modern lung cancer management.
Research Focus
Key Achievements
Top Papers
- 1